Skip to main content
Tom van Meerten
dr.

I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.

Onderzoek naar effect CAR T-cellen bij terugkerende beenmergkanker krijgt subsidie

Media coverage

Onderzoek naar effect CAR T-cellen bij terugkerende beenmergkanker krijgt subsidie

Media coverage

UMCG krijgt miljoenen voor nieuwe behandeling van beenmergkanker: ‘Je wint tijd’

Media coverage

Wat is de potentie van CAR-Tceltherapie bij terugkerende beenmergkanker?

Media contributions

UMCG krijgt miljoenen voor nieuwe behandeling van beenmergkanker: ‘Je wint tijd’

Media coverage